Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.91 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.91 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.84 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.81 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.58 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.58 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992188 | 0.98 | LTA4H (0.89) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL4453239 | 0.92 | HRH3 (0.89) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL21814264 | 0.91 | HRH3 (0.86) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL491607 | 0.91 | HRH3 (0.86) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL5856034 | 0.90 | HRH3 (0.84) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL490968 | 0.90 | HRH3 (1.00) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL4994427 | 0.90 | HRH3 (0.94) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL5857282 | 0.88 | HRH3 (0.97) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL520019 | 0.88 | LTA4H (0.72) | LTA4HPTGS2PTGS1KDM4EALDH1A1 | |
| SCHEMBL519451 | 0.87 | LTA4H (0.71) | LTA4HPTGS2PTGS1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118176195-A | Pyrazolo [3,4-d ] pyrimidine-3-ketone compound and medical application thereof | 正大天晴药业集团股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-113754591-B | HDAC, JAK and BET three-target inhibitor and preparation method and application thereof | 山东大学 | 2024-01-05 | — | — | CN | disclosed |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| EP-3755696-B1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2022-12-22 | — | — | US | disclosed |
| CN-113754591-A | HDAC, JAK and BET three-target inhibitor and preparation method and application thereof | 山东大学 | 2021-12-07 | — | — | CN | disclosed |
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | SAMUMED, LLC (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3755696-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | Samumed, LLC (US) | 2020-12-30 | — | — | EP | disclosed |
| WO-2004026823-A1 | AMIDE AND SULFONAMIDE LIGANDS FOR THE ESTROGEN RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CHU XIN-JIE (US) | 2004-01-08 | — | — | US | disclosed |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003097048-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003033476-A1 | PYRIMIDINONES AS MELANIN CONCENTRATING HORMONE RECEPTOR 1 | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003027102-A1 | 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-0997460-B1 | Benzothiophene compounds as antithrombotic agents and intermediates | LILLY CO ELI (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6133262-A | 3-AMINOBENZO(B)THIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0997460-A1 | Benzothiophene compounds as antithrombotic agents and intermediates | ELI LILLY AND COMPANY (US) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199478-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | LTA4H 4513/4885PTGS2 1351/4885PTGS1 1345/4885 |
| US-10934297-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | LTA4H 3768/4885PTGS2 3195/4885PTGS1 2888/4885 |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | LTA4H 3768/4885PTGS2 3195/4885PTGS1 2888/4885 |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | LTA4H 3768/4885PTGS2 3195/4885PTGS1 2888/4885 |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CDK4, CDK1, CDK2 | LTA4H 2159/4885PTGS2 2947/4885PTGS1 1969/4885 |
| US-20030225152-A1 | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | ERBB2, MKI67, CDK2 | LTA4H 4513/4885PTGS2 1351/4885PTGS1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.